Published in J Infect Dis on December 02, 2013
Regulation of Interferon-Stimulated Gene BST2 by a lncRNA Transcribed from a Shared Bidirectional Promoter. Front Immunol (2015) 0.90
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. J Virol (2015) 0.90
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth. Oncotarget (2016) 0.76
Spontaneous and natural cytotoxicity receptor-mediated cytotoxicity are effector functions of distinct natural killer subsets in hepatitis C virus-infected chimpanzees. Clin Exp Immunol (2016) 0.75
HBD-3 induces NK cell activation, IFN-γ secretion and mDC dependent cytolytic function. Cell Immunol (2015) 0.75
CD56(bright) NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections. J Leukoc Biol (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods (2004) 6.89
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology (2009) 2.66
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol (2010) 1.78
Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol (2005) 1.62
Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut (2008) 1.47
Race- and gender-related variation in natural killer p46 expression associated with differential anti-hepatitis C virus immunity. Hepatology (2012) 1.41
Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology (2009) 1.40
Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol (1997) 1.38
Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet (2009) 1.31
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett (2007) 1.20
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol (2011) 1.19
Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol (2010) 1.15
Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment. Biochem Biophys Res Commun (2010) 1.13
Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol (2009) 1.09
Increased frequencies of activating natural killer receptors are associated with liver injury in individuals who do not eliminate hepatitis C virus. Tissue Antigens (2007) 1.02
Natural killer cells suppress full cycle HCV infection of human hepatocytes. J Viral Hepat (2008) 1.02
NK sensitivity of neuroblastoma cells determined by a highly sensitive coupled luminescent method. Biochem Biophys Res Commun (2005) 0.92
Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol (2009) 0.92
Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline. J Infect Dis (2012) 0.86
Pharmacogenomics. Gene variants affect hepatitis C treatment, but link is elusive. Science (2010) 0.86
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Complex modulation of cell type-specific signaling in response to type I interferons. Immunity (2006) 4.48
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol (2008) 3.14
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis (2007) 3.05
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr (2006) 2.56
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis (2011) 2.35
Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood (2007) 2.21
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood (2012) 2.03
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One (2008) 1.83
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57
Characterizing HIV transmission networks across the United States. Clin Infect Dis (2012) 1.54
Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement. J Infect Dis (2005) 1.47
TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol (2007) 1.45
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS (2012) 1.38
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis (2013) 1.31
High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. J Acquir Immune Defic Syndr (2013) 1.23
Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One (2013) 1.19
HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS (2002) 1.15
Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Curr HIV Res (2008) 1.14
Moderate- and low-intensity co-infections by intestinal helminths and Schistosoma mansoni, dietary iron intake, and anemia in Brazilian children. Am J Trop Med Hyg (2006) 1.13
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther (2010) 1.13
Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol (2012) 1.13
Determinants of protection among HIV‐exposed seronegative persons: an overview. J Infect Dis (2010) 1.13
HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr (2012) 1.12
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis (2011) 1.11
Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr (2012) 1.11
Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. Blood (2009) 1.10
TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol (2007) 1.08
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One (2012) 1.06
Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis (2011) 1.05
Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. J Acquir Immune Defic Syndr (2015) 1.05
Peripheral blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C virus infection. J Immunol (2010) 1.04
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS (2011) 1.03
Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viremic human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function. J Virol (2009) 1.03
Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS (2013) 1.02
HIV pathogenesis: the host. Cold Spring Harb Perspect Med (2012) 1.02
Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol (2008) 1.02
HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells. J Infect Dis (2006) 1.01
Measuring morbidity in schistosomiasis mansoni: relationship between image pattern, portal vein diameter and portal branch thickness in large-scale surveys using new WHO coding guidelines for ultrasound in schistosomiasis. Trop Med Int Health (2003) 1.01
Low heritable component of risk for infection intensity and infection-associated disease in urinary schistosomiasis among Wadigo village populations in Coast Province, Kenya. Am J Trop Med Hyg (2004) 1.01
HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis (2014) 1.00
Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol (2005) 0.99
The relative influence of polyparasitism, environment, and host factors on schistosome infection. Am J Trop Med Hyg (2007) 0.99
Soluble CD14 is a nonspecific marker of monocyte activation. AIDS (2015) 0.99
CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. J Immunol Methods (2004) 0.98
Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. Clin Diagn Lab Immunol (2005) 0.97
Analysis of Schistosoma mansoni population structure using total fecal egg sampling. J Parasitol (2009) 0.96
Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS One (2011) 0.96
Long-term genetic stability and population dynamics of laboratory strains of Schistosoma mansoni. J Parasitol (2010) 0.96
Roles of IKK-beta, IRF1, and p65 in the activation of chemokine genes by interferon-gamma. J Interferon Cytokine Res (2009) 0.95
Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis (2011) 0.93
Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS (2013) 0.92
Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol (2009) 0.92
Blautia and Prevotella sequences distinguish human and animal fecal pollution in Brazil surface waters. Environ Microbiol Rep (2014) 0.90
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS (2013) 0.90
Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells. PLoS One (2011) 0.89
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. J Infect Dis (2012) 0.88
Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin α6β1 in glioblastoma. Cancer Res (2012) 0.88
[Risk factors for iron-deficiency anemia in children and adolescents with intestinal helminthic infections]. Rev Panam Salud Publica (2003) 0.87
Can HIV-1 superinfection compromise antiretroviral therapy? AIDS (2004) 0.87
Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. Blood (2013) 0.86
Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline. J Infect Dis (2012) 0.86
Influence of hepatitis C virus coinfection on CD4⁺ T cells of HIV-infected patients receiving HAART. AIDS (2014) 0.86
Characteristics of the human host have little influence on which local Schistosoma mansoni populations are acquired. PLoS Negl Trop Dis (2013) 0.85
Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. J Acquir Immune Defic Syndr (2016) 0.84
Activation of a subset of genes by IFN-gamma requires IKKbeta but not interferon-dependent activation of NF-kappaB. J Interferon Cytokine Res (2007) 0.84
A quantitative proteomic approach for detecting protein profiles of activated human myeloid dendritic cells. J Immunol Methods (2011) 0.84
Dengue hemorrhagic fever is associated with polymorphisms in JAK1. Eur J Hum Genet (2010) 0.83
A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults. AIDS Res Hum Retroviruses (2011) 0.83
Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. Expression of IFNAR2c tyrosine mutants in U5A cells. J Biol Chem (2001) 0.83
Volumetric capnography and chronic obstructive pulmonary disease staging. Int J Chron Obstruct Pulmon Dis (2007) 0.83
Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrob Agents Chemother (2011) 0.83